MR evaluation of response to targeted treatment in cancer cells

NMR in Biomedicine

Volumn 24, Issue 6, 2011, Pages 648-672

  Podo, Franca ^a   Canevari, Silvana ^b   Canese, Rossella ^a   Pisanu, Maria Elena ^a   Ricci, Alessandro ^a   Iorio, Egidio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cancer cells; Cell signaling; MRS; Pharmacodynamic biomarkers; Phosphatidylcholine cycle; Targeted therapies

Indexed keywords

CANCER CELLS; CELL SIGNALING; MRS; PHARMACODYNAMIC BIOMARKERS; PHOSPHATIDYLCHOLINE; TARGETED THERAPIES;

BIOCHEMISTRY; CATALYSTS; CELL MEMBRANES; ENZYMES; GENE EXPRESSION; GLUCOSE; METABOLISM; PHARMACODYNAMICS; PHOSPHOLIPIDS; PHOSPHORYLATION; TUMORS;

DISEASES;

1,4 ( 4,4' BIS(( 4 (DIMETHYLAMINE)PYRIDINIUM 1 YL)METHYL)DIPHENYL)BUTANE DIBROMIDE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 17 AMINO 17 DEMETHOXYGELDANAMYCIN; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 FLUORO SUBEROYLANILIDE HYDROXAMIC ACID; ANTINEOPLASTIC AGENT; CELL RECEPTOR; CERULENIN; CHOLINE; CHOLINE KINASE; DACINOSTAT; ENZYME; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IMATINIB; INDOMETACIN; PHENYLBUTYRIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE C; PHOSPHOLIPID; PHOSPHORYLCHOLINE; PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; TANESPIMYCIN; TETRAHYDROLIPSTATIN; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; WORTMANNIN;

APOPTOSIS; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL METABOLISM; CELL PH; CELL PROLIFERATION; DEACYLATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME SYNTHESIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IN VITRO STUDY; INFLAMMATION; ION TRANSPORT; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACODYNAMICS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; CHOLINE; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 79960778921     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1658     Document Type: Review

References (239)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell, 2000; 100(1): 57-70.
2. Canevari S, Gariboldi M, Reid JF, Bongarzone I, Pierotti MA. Molecular predictors of response and outcome in ovarian cancer. Crit. Rev. Oncol. Hematol. 2006; 60(1): 19-37.
3. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 2008; 359(19): 1995-2004.
4. Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br. J. Cancer, 2009; 100(10): 1517-1522.
5. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat. Rev. Cancer, 2004; 4(7): 551-561.
6. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 2009; 15(2): 431-440.
7. Yanes O, Clark J, Wong DM, Patti GJ, Sanchez-Ruiz A, Benton HP, Trauger SA, Desponts C, Ding S, Siuzdak G. Metabolic oxidation regulates embryonic stem cell differentiation. Nat. Chem. Biol. 2010; 6: 411-417.
8. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 2009; 457(7231): 910-914.
9. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek S, Konsgen D, Dietel M, Fiehn O. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006; 66(22): 10 795-10 804.
10. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992; 5(5): 303-324.
11. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12(7): 413-439.
12. Serkova NJ, Spratlin JL, Eckhardt SG. NMR-based metabolomics: translational application and treatment of cancer. Curr. Opin. Mol. Ther. 2007; 9(6): 572-585.
13. Mountford CE, Doran S, Lean CL, Russell P. Proton MRS can determine the pathology of human cancers with a high level of accuracy. Chem. Rev. 2004; 104(8): 3677-3704.
14. Gillies RJ, Morse DL. In vivo magnetic resonance spectroscopy in cancer. Annu. Rev. Biomed. Eng. 2005; 7: 287-326.
15. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol. Pharm. 2006; 3(5): 496-506.
16. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics, 2006; 7(7): 1109-1123.
17. Merz AL, Serkova NJ. Use of nuclear magnetic resonance-based metabolomics in detecting drug resistance in cancer. Biomark. Med. 2009; 3(3): 289-306.
18. Beloueche-Babari M, Chung YL, Al-Saffar NM, Falck-Miniotis M, Leach MO. Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy. Br. J. Cancer, 2010; 102(1): 1-7.
19. Glunde K, Artemov D, Penet MF, Jacobs MA, Bhujwalla ZM. Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem. Rev. 2010; 110(5): 3043-3059.
20. Anderkjaer-Larsen JH, Fridlund B, Gram A, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of over 10, 000 times in liquid state NMR. Proc. Natl. Acad. Sci. USA, 2003; 100(18): 10 158-10 163.
21. Gadian DG. NMR and its Applications to Living Systems, 2nd revised edn. Oxford Science Publications: Oxford, 1996.
22. Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int. J. Biochem. Cell Biol. 2007; 39(7-8): 1358-1366.
23. Shaw RJ. Glucose metabolism and cancer. Curr. Opin. Cell Biol. 2006; 18(6): 598-608.
24. Wallace DC. Mitochondria and cancer: Warburg addressed. Cold Spring Harb. Symp. Quant. Biol. 2005; 70: 363-374.
25. 1H NMR visible lipids in the life and death of cells. Trends Biochem. Sci. 2000; 25(8): 357-362.
26. Greenberg AS, Obin MS. Many roads lead to the lipid droplet. Cell Metab. 2008; 7(6): 472-473.
27. 1H NMR-visible lipid bodies in HuT 78 apoptotic cells. Biochim. Biophys. Acta, 2003; 1634(1-2): 1-14.
28. Milkevitch M, Beardsley NJ, Delikatny EJ. Phenylbutyrate induces apoptosis and lipid accumulations via a peroxisome proliferator-activated receptor gamma-dependent pathway. NMR Biomed. 2010; 23(5): 473-479.
29. Pelech SL, Vance DE. Signal transduction via phosphatidylcholine cycle. Trends Biochem. Sci. 1989; 14: 28-30.
30. 31P MRS of experimental tumours. NMR Biomed. 1993; 6(6): 345-365.
31. Vance JE, Vance DE. Phospholipid biosynthesis in mammalian cells. Biochem. Cell Biol. 2004; 82(1): 113-128.
32. Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene, 1993; 8(11): 2959-2968.
33. Chung T, Huang JS, Mukherjee JJ, Crilly KS, Kiss Z. Expression of human choline kinase in NIH 3T3 fibroblasts increases the mitogenic potential of insulin and insulin-like growth factor I. Cell Signal, 2000; 12(5): 279-288.
34. Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog. Lipid Res. 2004; 43(3): 266-281.
35. Janardhan S, Srivani P, Sastry GN. Choline kinase: an important target for cancer. Curr. Med. Chem. 2006; 13(10): 1169-1186.
36. Ramoni C, Spadaro F, Barletta B, Dupuis ML, Podo F. Phosphatidylcholine-specific phospholipase C in mitogen-stimulated fibroblasts. Exp. Cell Res. 2004; 299(2): 370-382.
37. Spadaro F, Ramoni C, Mezzanzanica D, Miotti S, Alberti P, Cecchetti S, Iorio E, Dolo V, Canevari S, Podo F. Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res. 2008; 68(16): 6541-6549.
38. Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, Venturini E, Glunde K, Bhujwalla ZM, Mezzanzanica D, Canevari S. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cell. Cancer Res. 2010; 70(5): 2126-2135.
39. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J. Cell Biochem. 2003; 90(3): 525-533.
40. Podo F, Sardanelli F, Iorio E, Canese R, Carpinelli G, Fausto A, Canevari S. Abnormal choline phospholipid metabolism in breast and ovary cancer: molecular bases for noninvasive imaging approaches. Curr. Med. Imaging Rev. 2007; 3: 123-137.
41. Gribbestad I, Glunde K. Choline metabolism in cancer. NMR Biomed. in press.
42. Franks SE, Smith MR, Arias-Mendoza F, Shaller C, Padavic-Shaller K, Kappler F, Zhang Y, Negendank WG, Brown TR. Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytes. Leuk. Res. 2002; 26(10): 919-926.
43. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999; 59(1): 80-84.
44. Mori N, Delsite R, Natarajan K, Kulawiec M, Bhujwalla ZM, Singh KK. Loss of p53 function in colon cancer cells results in increased phosphocholine and total choline. Mol. Imaging, 2004; 3(4): 319-323.
45. 31P nuclear magnetic resonance study in vivo and in vitro. Magn. Reson. Med. 1999; 41(5): 897-903.
46. 13C-nuclear magnetic resonance (NMR) spectroscopy study. Cancer Res. 1995; 55(22): 5140-5145.
47. Ting YL, Sherr D, Degani H. Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res. 1996; 16(3B): 1381-1388.
48. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001; 61(9): 3599-3603.
49. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 2002; 62(7): 1966-1970.
50. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res. 2005; 65(8): 3356-3363.
51. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005; 65(20): 9369-9376.
52. Eliyahu G, Kreizman T, Degani H. Phosphocholine as a biomarker of breast cancer: molecular and biochemical studies. Int. J. Cancer, 2007; 120(8): 1721-1730.
53. Li Z, Vance DE. Phosphatidylcholine and choline homeostasis. J. Lipid Res. 2008; 49(6): 1187-1194.
54. Tso P, Fujimoto K. The absorption and transport of lipids by the small intestine. Brain Res. Bull. 1991; 27(3-4): 477-482.
55. Morse DL, Carroll D, Day S, Gray H, Sadarangani P, Murthi S, Job C, Baggett B, Raghunand N, Gillies RJ. Characterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway. NMR Biomed. 2009; 22(1): 114-127.
56. Vance DE. Phospholipid biosynthesis in eukaryotes. In: Vance DE, Vance JE (eds). Biochemistry of Lipids, Lipoproteins and Membranes. Elsevier Science: Amsterdam, 2002; pp. 205-323.
57. Warden CH, Friedkin M. Regulation of choline kinase activity and phosphatidylcholine biosynthesis by mitogenic growth factors in 3T3 fibroblasts. J. Biol. Chem. 1985; 260(10): 6006-6011.
58. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, Rosell R, Lacal J. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Commun. 2002; 296(3): 580-583.
59. Ramirez de Molina A, Bañez-Coronel M, Gutierrez R, Rodriguez-Gonzalez A, Olmeda D, Megias D, Lacal JC. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res. 2004; 64(18): 6732-6739.
60. Ramirez de Molina A, Rodriguez-Gonzalez A, Penalva V, Lucas L, Lacal JC. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells. Biochem. Biophys. Res. Commun. 2001; 285(4): 873-879.
61. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene, 2002; 21(6): 937-946.
62. Chua BT, Gallego-Ortega D, Ramirez de Molina A, Ullrich A, Lacal JC, Downward J. Regulation of Akt(ser473) phosphorylation by choline kinase in breast carcinoma cells. Mol. Cancer, 2009; 8: 131.
63. Jimenez B, del Peso L, Montaner S, Esteve P, Lacal JC. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J. Cell Biochem. 1995; 57(1): 141-149.
64. Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sanchez JJ, Lacal JC. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene, 2002; 21(27): 4317-4322.
65. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Casado E, Garcia-Cabezas MA, Sanchez JJ, Nistal M, Rosell R, Gonzalez-Baron M, Lacal JC. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol. 2007; 8(10): 889-897.
66. Hernando E, Sarmentero-Estrada J, Koppie T, Belda-Iniesta C, Ramirez de Molina V, Cejas P, Ozu C, Le C, Sanchez JJ, Gonzalez-Baron M, Koutcher J, Cordon-Cardo C, Bochner BH, Lacal JC, Ramirez de Molina A. A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas. Oncogene, 2009; 28(26): 2425-2435.
67. Exton JH, Phospholipase D. Biochim. Biophys. Acta, 1998; 1436(1-2): 105-115.
68. Rizzo MA, Shome K, Vasudevan C, Stolz DB, Sung TC, Frohman MA, Watkins SC, Romero G. Phospholipase D and its product, phosphatidic acid, mediate agonist-dependent raf-1 translocation to the plasma membrane and the activation of the mitogen-activated protein kinase pathway. Biol. Chem. 1999; 274(2): 1131-1139.
69. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC Jr, Mills GB, Fang X. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006; 66(5): 2740-2748.
70. Hammond SM, Jenco JM, Nakashima S, Cadwallader K, Gu Q, Cook S, Nozawa Y, Prestwich GD, Frohman MA, Morris AJ. Characterization of two alternately spliced forms of phospholipase D1. Activation of the purified enzymes by phosphatidylinositol 4, 5-bisphosphate, ADP-ribosylation factor, and Rho family monomeric GTP-binding proteins and protein kinase C-alpha. J. Biol. Chem. 1997; 272(6): 3860-3868.
71. Colley WC, Sung TC, Roll R, Jenco J, Hammond SM, Altshuller Y, Bar-Sagi D, Morris AJ, Frohman MA. Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr. Biol. 1997; 7(3): 191-201.
72. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Mol. Cancer Res. 2003; 1(11): 789-800.
73. Uchida N, Okamura S, Nagamachi Y, Yamashita S. Increased phospholipase D activity in human breast cancer. J. Cancer Res. Clin. Oncol. 1997; 123(5): 280-285.
74. Noh DY, Ahn SJ, Lee RA, Park IA, Kim JH, Suh PG, Ryu SH, Lee KH, Han JS. Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett. 2000; 161(2): 207-214.
75. Lucas L, Penalva V, Ramirez de Molina A, Del Peso L, Lacal JC. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1. Int. J. Oncol. 2002; 21(3): 477-485.
76. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol. Cell Biol. 2009; 29(6): 1411-1420.
77. Yalcin A, Clem B, Makoni S, Clem A, Nelson K, Thornburg J, Siow D, Lane AN, Brock SE, Goswami U, Eaton JW, Telang S, Chesney J. Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling. Oncogene, 2010; 29(1): 139-149.
78. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004; 64(12): 4270-4276.
79. Bjørkøy G, Overvatn A, Diaz-Meco MT, Moscat J, Johansen T. Evidence for a bifurcation of the mitogenic signaling pathway activated by Ras and phosphatidylcholine-hydrolyzing phospholipase C. J. Biol. Chem. 1995; 270(36): 21 299-21 306.
80. Exton JH. Phosphatidylcholine breakdown and signal transduction. Biochim. Biophys. Acta, 1994; 1212(1): 26-42.
81. van Dijk MC, Muriana FJ, de Widt J, Hilkmann H, van Blitterswijk WJ. Involvement of phosphatidylcholine-specific phospholipase C in platelet-derived growth factor-induced activation of the mitogen-activated protein kinase pathway in Rat-1 fibroblasts. J. Biol. Chem. 1997; 272(17): 11 011-11 016.
82. Kahle PJ, Shooter EM, Johnson RM, Verity AN. Phosphatidylcholine-specific phospholipase inhibitor D609 differentially affects MAP kinases and immediate-early genes in PC12 cells. Cell Signal, 1998; 10(5): 321-330.
83. Li F, Wu N, Su RB, Zheng JQ, Xu B, Lu XQ, Cong B, Li J. Involvement of phosphatidylcholine-selective phospholipase C in activation of mitogen-activated protein kinase pathways in imidazoline receptor antisera-selected protein. J. Cell Biochem. 2006; 98(6): 1615-1628.
84. Ramoni C, Spadaro F, Menegon M, Podo F. Cellular localization and functional role of phosphatidylcholine-specific phospholipase C in NK cells. J. Immunol. 2001; 167(5): 2642-2650.
85. Spadaro F, Cecchetti S, Sanchez M, Ausiello CM, Podo F, Ramoni C. Expression and role of phosphatidylcholine-specific phospholipase C in human NK and T lymphocyte subsets. Eur. J. Immunol. 2006; 36(12): 3277-3287.
86. Cecchetti S, Spadaro F, Lugini L, Podo F, Ramoni C. Functional role of phosphatidylcholine-specific phospholipase C in regulating CD16 membrane expression in natural killer cells. Eur. J. Immunol. 2007; 37(10): 2912-2922.
87. Luft T, Rodionova E, Maraskovsky E, Kirsch M, Hess M, Buchholtz C, Goerner M, Schnurr M, Skoda R, Ho AD. Adaptive functional differentiation of dendritic cells: integrating the network of extra- and intracellular signals. Blood, 2006; 107(12): 4763-4769.
88. Cifone MG, Roncaioli P, De Maria R, Camarda G, Santoni A, Ruberti G, Testi R. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J. 1995; 14(23): 5859-5868.
89. Liu X, Zhao Q, Araki S, Zhang S, Miao J. Contrasting effects of phosphatidylinositol- and phosphatidylcholine-specific phospholipase C on apoptosis in cultured endothelial cells. Endothelium, 2006; 13(3): 205-211.
90. Paris L, Cecchetti S, Spadaro F, Abalsamo L, Lugini L, Pisanu ME, Iorio E, Natali PG, Ramoni C, Podo F. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res. 2010; 12(3): R27.
91. Agris PF, Campbell ID. Proton nuclear magnetic resonance of intact Friend leukemia cells: phosphorylcholine increase during differentiation. Science, 1982; 216(4552): 1325-1327.
92. 31P NMR study. FEBS Lett. 1984; 176(1): 88-92.
93. 1H NMR studies. Isr. J. Chem. 1992; 32: 291-298.
94. Ferretti A, Podo F, Carpinelli G, Chen L, Borghi P, Masella R. Detection of neutral active phosphatidylcholine-specific phospholipase C in Friend leukemia cells before and after erythroid differentiation. Anticancer Res. 1993; 13(6A): 2309-2317.
95. Galons JP, Fantini J, Vion-Dury J, Cozzone PJ, Canioni P. Metabolic changes in undifferentiated and differentiated human colon adenocarcinoma cells studied by multinuclear magnetic resonance spectroscopy. Biochimie, 1989; 71(8): 949-961.
96. Milkevitch M, Shim H, Pilatus U, Pickup S, Wehrle JP, Samid D, Poptani H, Glickson JD, Delikatny EJ. Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim. Biophys. Acta, 2005; 1734(1): 1-12.
97. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 2001; 8(12): 1505-1511.
98. Davis T, Kennedy C, Chiew YE, Clarke CL, deFazio A. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res. 2000; 6(11): 4334-4342.
99. Milkevitch M, Jeitner TM, Beardsley NJ, Delikatny EJ. Lovastatin enhances phenylbutyrate-induced MR-visible glycerophosphocholine but not apoptosis in DU145 prostate cells. Biochim. Biophys. Acta, 2007; 1771(9): 1166-1176.
100. Yu J, Thomson JA. Pluripotent stem cell lines. Genes Dev. 2008; 22(15): 1987-1997.
101. Jansen JF, Shamblott MJ, van Zijl PC, Lehtimaki KK, Bulte JW, Gearhart JD, Hakumaki JM. Stem cell profiling by nuclear magnetic resonance spectroscopy. Magn. Reson. Med. 2006; 56(3): 666-670.
102. Takahashi K, Ichisaka T, Yamanaka S. Identification of genes involved in tumor-like properties of embryonic stem cells. Methods Mol. Biol. 2006; 329: 449-458.
103. Romanska HM, Tiziani S, Howe RC, Gunther UL, Gulzar Z, Lalani el-N. Nuclear magnetic resonance detects phosphoinositide 3-kinase/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts. Neoplasia, 2009; 11(12): 1301-1308.
104. Ward S, Sotsios Y, Dowden J, Bruce I, Finan P. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem. Biol. 2003; 10(3): 207-213.
105. Paling NR, Wheadon H, Bone HK, Welham MJ. Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. J. Biol. Chem. 2004; 279(46): 48 063-48 070.
106. Takahashi K, Murakami M, Yamanaka S. Role of the phosphoinositide 3-kinase pathway in mouse embryonic stem (ES) cells. Biochem. Soc. Trans. 2005; 33 (Pt 6): 1522-1525.
107. Kim SJ, Cheon SH, Yoo SJ, Kwon J, Park JH, Kim CG, Rhee K, You S, Lee JY, Roh SI, Yoon HS. Contribution of the PI3K/Akt/PKB signal pathway to maintenance of self-renewal in human embryonic stem cells. FEBS Lett. 2005; 579(2): 534-540.
108. Watanabe S, Umehara H, Murayama K, Okabe M, Kimura T, Nakano T. Activation of Akt signaling is sufficient to maintain pluripotency in mouse and primate embryonic stem cells. Oncogene, 2006; 25(19): 2697-2707.
109. Wang N, Xie K, Huo S, Zhao J, Zhang S, Miao J. Suppressing phosphatidylcholine-specific phospholipase C and elevating ROS level, NADPH oxidase activity and Rb level induced neuronal differentiation in mesenchymal stem cells. J. Cell Biochem. 2007; 100(6): 1548-1557.
110. Wang N, Sun C, Huo S, Zhang Y, Zhao J, Zhang S, Miao J. Cooperation of phosphatidylcholine-specific phospholipase C and basic fibroblast growth factor in the neural differentiation of mesenchymal stem cells in vitro. Int. J. Biochem. Cell Biol. 2008; 40(2): 294-306.
111. Kunz LA, Groebe K, Mueller-Klieser W. Oncogene-associated growth behavior and oxygenation of multicellular spheroids from rat embryo fibroblasts. Adv. Exp. Med. Biol. 1994; 345: 359-366.
112. Biaglow JE, Cerniglia G, Tuttle S, Bakanauskas V, Stevens C, McKenna G. Effect of oncogene transformation of rat embryo cells on cellular oxygen consumption and glycolysis. Biochem. Biophys. Res. Commun. 1997; 235(3): 739-742.
113. 13C NMR studies. Proc. Natl. Acad. Sci. USA, 1989; 86(14): 5585-5589.
114. 31P-magnetic resonance spectroscopy study. Cancer Res. 2001; 61(20): 7536-7543.
115. Pilatus U, Aboagye E, Artemov D, Mori N, Ackerstaff E, Bhujwalla ZM. Real-time measurements of cellular oxygen consumption, pH, and energy metabolism using nuclear magnetic resonance spectroscopy. Magn. Reson. Med. 2001; 45(5): 749-755.
116. Greijer AE, van der Groep P, Kemming D, Shvarts A, Semenza GL, Meijer GA, van de Wiel MA, Belien JA, van Diest PJ, van der Wall E. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J. Pathol. 2005; 206(3): 291-304.
117. Neeman M. Hypoxic stress and cancer: imaging the axis of evil in tumor metastasis. NMR Biomed. 2011; DOI: 10.1002/nbm.1632.
118. Glunde K, Shah T, Winnard PT Jr, Raman V, Takagi T, Vesuna F, Artemov D, Bhujwalla ZM. Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res. 2008; 68(1): 172-180.
119. Kobayashi H. Molecular imaging of tumor invasion and metastases: the role of MRI. NMR Biomed. 2010; DOI: 10.1002/nbm.1590.
120. Artemov D, Pilatus U, Chu S, Mori N, Nelson JB, Bhujwalla ZM. Dynamics of prostate cancer cell invasion studied in vitro by NMR microscopy. Magn. Reson. Med. 1999; 42(2): 277-282.
121. Pilatus U, Ackerstaff E, Artemov D, Mori N, Gillies RJ, Bhujwalla ZM. Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: the Metabolic Boyden Chamber. Neoplasia, 2000; 2(3): 273-279.
122. Lupulescu A. Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot. Essent. Fatty Acids, 1996; 54(2): 83-94.
123. Vane JR, Botting RM. Mechanism of action of antiinflammatory drugs. Int. J. Tissue React. 1998; 20(1): 3-15.
124. Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky DJ, Lyn P, Leavy J, Witte L, Joseph-Silverstein J, Furie MB, Torcia G, Cozzolino F, Kamada T, Stern DM. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc. Natl. Acad. Sci. USA, 1995; 92 10 4606-4610.
125. Hofer SO, Molema G, Hermens RA, Wanebo HJ, Reichner JS, Hoekstra HJ. The effect of surgical wounding on tumour development. Eur. J. Surg. Oncol. 1999; 25(3): 231-243.
126. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 2009; 30(3): 377-386.
127. Natarajan K, Mori N, Artemov D, Aboagye EO, Chacko VP, Bhujwalla ZM. Phospholipid profiles of invasive human breast cancer cells are altered towards a less invasive phospholipid profile by the anti-inflammatory agent indomethacin. Adv. Enzyme Regul. 2000; 40: 271-284.
128. Natarajan K, Mori N, Artemov D, Bhujwalla ZM. Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and Nm23 expression. Neoplasia, 2002; 4(5): 409-416.
129. 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn. Reson. Med. 2002; 48(5): 819-825.
130. Glunde K, Jie C, Bhujwalla ZM. Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia, 2006; 8(9): 758-771.
131. Mori N, Natarajan K, Chacko VP, Artemov D, Bhujwalla ZM. Choline phospholipid metabolites of human vascular endothelial cells altered by cyclooxygenase inhibition, growth factor depletion, and paracrine factors secreted by cancer cells. Mol. Imaging, 2003; 2(2): 124-130.
132. Gogas H, Kirkwood JM. Predictors of response to interferon therapy. Curr. Opin. Oncol. 2009; 21(2): 138-143.
133. Balkwill F. Tumour necrosis factor and cancer. Nat. Rev. Cancer, 2009; 9(5): 361-371.
134. 31P-nuclear magnetic resonance analysis of interferon-induced alterations of phospholipid metabolites in interferon-sensitive and interferon-resistant Friend leukemia cell tumors in mice. Cancer Res. 1986; 46(6): 2849-2857.
135. Podo F, Carpinelli G, Di Vito M, Giannini M, Proietti E, Fiers W, Gresser I, Belardelli F. Nuclear magnetic resonance analysis of tumor necrosis factor-induced alterations of phospholipid metabolites and pH in Friend leukemia cell tumors and fibrosarcomas in mice. Cancer Res. 1987; 47 (24 Pt 1): 6481-6489.
136. Bogin L, Papa MZ, Polak-Charcon S, Degani H. TNF-induced modulations of phospholipid metabolism in human breast cancer cells. Biochim. Biophys. Acta, 1998; 1392(2-3): 217-232.
137. Brahimi-Horn MC, Pouyssegur J. Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem. 2007; 43: 165-178.
138. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov. 2008; 7(2): 168-181.
139. De Milito A, Fais S. Proton pump inhibitors may reduce tumour resistance. Expert Opin. Pharmacother. 2005; 6(7): 1049-1054.
140. +-ATPases as a new strategy against cancer. Cancer Res. 2007; 67(22): 10 627-10 630.
141. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007; 99(19): 1441-1454.
142. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 2008; 49 (Suppl 2): 24S-42S.
143. Stubbs M, Rodrigues L, Howe FA, Wang J, Jeong KS, Veech RL, Griffiths JR. Metabolic consequences of a reversed pH gradient in rat tumors. Cancer Res. 1994; 54(15): 4011-4016.
144. +)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am. J. Physiol. 1993; 265 (4 Pt 1): C1015-C1029.
145. Smallbone K, Gavaghan DJ, Gatenby RA, Maini PK. The role of acidity in solid tumour growth and invasion. J. Theor. Biol. 2005; 235(4): 476-484.
146. Gerweck LE. Tumor pH: implications for treatment and novel drug design. Semin. Radiat. Oncol. 1998; 8(3): 176-182.
147. Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM, Gillies RJ. Enhancement of chemotherapy by manipulation of tumour pH. Br. J. Cancer, 1999; 80(7): 1005-1011.
148. McSheehy PM, Troy H, Kelland LR, Judson IR, Leach MO, Griffiths JR. Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics. Eur. J. Cancer, 2003; 39(4): 532-540.
149. Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 2006; 5(5): 1275-1279.
150. Raghunand N. Tissue pH measurement by magnetic resonance spectroscopy and imaging. Methods Mol. Med. 2006; 124: 347-364.
151. Ojugo AS, McSheehy PM, Stubbs M, Alder G, Bashford CL, Maxwell RJ, Leach MO, Judson IR, Griffiths JR. Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br. J. Cancer, 1998; 77(6): 873-879.
152. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today, 2000; 6(1): 15-19.
153. 19F nuclear magnetic resonance spectroscopy. Cancer Res. 1991; 51(20): 5770-5773.
154. McSheehy PM, Robinson SP, Ojugo AS, Aboagye EO, Cannell MB, Leach MO, Judson IR, Griffiths JR. Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo. Cancer Res. 1998; 58(6): 1185-1194.
155. McSheehy PM, Stubbs M, Griffiths JR. Role of pH in tumor-trapping of the anticancer drug 5-fluorouracil. Adv. Enzyme Regul. 2000; 40: 63-80.
156. McSheehy PM, Port RE, Rodrigues LM, Robinson SP, Stubbs M, van der Borns K, Peters GJ, Judson IR, Leach MO, Griffiths JR. Investigations in vivo of the effects of carbogen breathing on 5-fluorouracil pharmacokinetics and physiology of solid rodent tumours. Cancer Chemother. Pharmacol. 2005; 55(2): 117-128.
157. Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 2006; 66(13): 6699-6707.
158. De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Mina PD, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int. J. Cancer, 2009; 124(12): 2804-2812.
159. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Rey JM, Garcia-Garcia A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat. Rev. 2009; 35(8): 707-713.
160. Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 2009; 69(6): 2260-2268.
161. Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl. Cancer Inst. 2004; 96(22): 1702-1713.
162. Das M, Mishra D, Dhak P, Gupta S, Maiti TK, Basak A, Pramanik P. Biofunctionalized, phosphonate-grafted, ultrasmall iron oxide nanoparticles for combined targeted cancer therapy and multimodal imaging. Small, 2009; 5(24): 2883-2893.
163. Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv. Cancer Res. 2007; 96: 213-268.
164. Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, Maxwell RJ, McSheehy PM, Price PM, Zweit J. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J. Natl. Cancer Inst. 2006; 98(9): 580-598.
165. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005; 307(5706): 58-62.
166. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta, 2010; 1802(4): 396-405.
167. Bhakoo KK, Williams SR, Florian CL, Land H, Noble MD. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res. 1996; 56(20): 4630-4635.
168. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br. J. Cancer, 2001; 84(5): 691-696.
169. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 2000; 18(4): 927-941.
170. Leonard S, Beck L, Sinensky M. Inhibition of isoprenoid biosynthesis and the post-translational modification of pro-p21. J. Biol. Chem. 1990; 265(9): 5157-5160.
171. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000; 351 (Pt 1): 95-105.
172. Liu D, Hutchinson OC, Osman S, Price P, Workman P, Aboagye EO. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br. J. Cancer, 2002; 87(7): 783-789.
173. Geilen CC, Wieder T, Boremski S, Wieprecht M, Orfanos CE. c-Ha-ras oncogene expression increases choline uptake, CTP:phosphocholine cytidylyltransferase activity and phosphatidylcholine biosynthesis in the immortalized human keratinocyte cell line HaCaT. Biochim. Biophys. Acta, 1996; 1299(3): 299-305.
174. Bakovic M, Waite K, Vance DE. Oncogenic Ha-Ras transformation modulates the transcription of the CTP:phosphocholine cytidylyltransferase alpha gene via p42/44MAPK and transcription factor Sp3. J. Biol. Chem. 2003; 278(17): 14 753-14 761.
175. Ramirez De Molina A, Rodriguez-Gonzalez A, Lacal JC. Targeting new anticancer drugs within signalling pathways regulated by the Ras GTPase superfamily (Review). Int. J. Oncol. 2001; 19(1): 5-17.
176. Lacal JC, Moscat J, Aaronson SA. Novel source of 1, 2-diacylglycerol elevated in cells transformed by Ha-ras oncogene. Nature, 1987; 330(6145): 269-272.
177. Teegarden D, Taparowsky EJ, Kent C. Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras oncogene. J. Biol. Chem. 1990; 265(11): 6042-6047.
178. Cai H, Erhardt P, Szeberenyi J, Diaz-Meco MT, Johansen T, Moscat J, Cooper GM. Hydrolysis of phosphatidylcholine is stimulated by Ras proteins during mitogenic signal transduction. Mol. Cell Biol. 1992; 12(12): 5329-5335.
179. Cantley LC. The phosphoinositide 3-kinase pathway. Science, 2002; 296(5573): 1655-1657.
180. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2002; 2(7): 489-501.
181. Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene, 2008; 27(41): 5511-5526.
182. Beloueche-Babari M, Jackson LE, Al-Saffar NM, Eccles SA, Raynaud FI, Workman P, Leach MO, Ronen SM. Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol. Cancer Ther. 2006; 5(1): 187-196.
183. 13C magnetic resonance spectroscopy. Cancer Res. 2010; 70(4): 1296-1305.
184. Houghton PJ. Everolimus. Clin. Cancer Res. 2010; 16(5): 1368-1372.
185. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv. Cancer Res. 2000; 78: 31-101.
186. Wells A, Grandis JR. Phospholipase C-gamma1 in tumor progression. Clin. Exp. Metastasis, 2003; 20(4): 285-290.
187. Beloueche-Babari M, Peak JC, Jackson LE, Tiet MY, Leach MO, Eccles SA. Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells. Mol. Cancer Ther. 2009; 8(5): 1305-1311.
188. Peak JC, Jones NP, Hobbs S, Katan M, Eccles SA. Phospholipase C gamma 1 regulates the Rap GEF1-Rap1 signalling axis in the control of human prostate carcinoma cell adhesion. Oncogene, 2008; 27(20): 2823-2832.
189. Wakil SJ. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry, 1989; 28(11): 4523-4530.
190. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 2006; 66(12): 5977-5980.
191. Lupu R, Menendez JA. Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr. Pharm. Biotechnol. 2006; 7(6): 483-493.
192. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004; 64(6): 2070-2075.
193. Ross J, Najjar AM, Sankaranarayanapillai M, Tong WP, Kaluarachchi K, Ronen SM. Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol. Cancer Ther. 2008; 7(8): 2556-2565.
194. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer, 2007; 7(10): 763-777.
195. Neckers L. Heat shock protein 90: the cancer chaperone. J. Biosci. 2007; 32(3): 517-530.
196. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res. 2009; 15(1): 9-14.
197. Hwang M, Moretti L, Lu B. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr. Med. Chem. 2009; 16(24): 3081-3092.
198. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 1998; 42(4): 273-279.
199. Chung YL, Troy H, Banerji U, Jackson LE, Walton MI, Stubbs M, Griffiths JR, Judson IR, Leach MO, Workman P, Ronen SM. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl. Cancer Inst. 2003; 95(21): 1624-1633.
200. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 1998; 12(5): 599-606.
201. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu. Rev. Biochem. 2001; 70: 81-120.
202. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer, 2001; 1(3): 194-202.
203. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009; 27(32): 5459-5468.
204. Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, Workman P, Leach MO, Beloueche-Babari M. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia, 2008; 10(4): 303-313.
205. Sankaranarayanapillai M, Tong WP, Maxwell DS, Pal A, Pang J, Bornmann WG, Gelovani JG, Ronen SM. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol. Cancer Ther. 2006; 5(5): 1325-1334.
206. Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin. Cancer Res. 2007; 13(4): 1089-1097.
207. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin. Cancer Res. 2004; 10(19): 6661-6668.
208. Serkova N, Boros LG. Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. Am. J. Pharmacogenomics, 2005; 5(5): 293-302.
209. Kominsky DJ, Klawitter J, Brown JL, Boros LG, Melo JV, Eckhardt SG, Serkova NJ. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin. Cancer Res. 2009; 15(10): 3442-3450.
210. 13C magnetic resonance imaging. Progr. Nucl. Magn. Reson. Spectrosc. 2009; 55: 285-295.
211. 13C lactate, pyruvate and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008; 68(20): 8607-8615.
212. Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs, 2001; 4(4): 419-426.
213. Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res. 2005; 65(23): 11 034-11 043.
214. Mori N, Glunde K, Takagi T, Raman V, Bhujwalla ZM. Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res. 2007; 67(23): 11 284-11 290.
215. Krishnamachary B, Glunde K, Wildes F, Mori N, Takagi T, Raman V, Bhujwalla ZM. Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res. 2009; 69(8): 3464-3471.
216. Bañez-Coronel M, Ramirez de Molina A, Rodriguez-Gonzalez A, Sarmentero J, Ramos MA, Garcia-Cabezas MA, Garcia-Oroz L, Lacal JC. Choline kinase alpha depletion selectively kills tumoral cells. Curr. Cancer Drug Targets, 2008; 8(8): 709-719.
217. Rodriguez-Gonzalez A, Ramirez deMolina, Fernandez A, Ramos F, del Carmen MA, Nunez M, Campos J, Lacal JC. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene, 2003; 22(55): 8803-8812.
218. Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene, 2004; 23(50): 8247-8259.
219. Al-Saffar NM, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res. 2006; 66(1): 427-434.
220. Podo F, Ferretti A, Knijn A, Zhang P, Ramoni C, Barletta B, Pini C, Baccarini S, Pulciani S. Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Anticancer Res. 1996; 16(3B): 1399-1412.
221. 31P NMR. NMR Biomed. 2009; 22(4): 456-461.
222. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc. Drug Rev. 2006; 24(3-4): 261-274.
223. Weber WA. Positron emission tomography as an imaging biomarker. J. Clin. Oncol. 2006; 24: 3283-3292.
224. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur. J. Radiol. 2009; 70(3): 382-392.
225. Ahlgren S, Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr. Pharm. Biotechnol. 2010; 11(6): 581-589.
226. Ng TS, Procissi D, Wu Y, Jacobs RE. A robust coregistration method for in vivo studies using a first generation simultaneous PET/MR scanner. Med. Phys. 2010; 37(5): 1995-2003.
227. Matsumoto S, Yasui H, Batra S, Kinoshita Y, Bernardo M, Munasinghe JP, Utsumi H, Choudhuri R, Devasahayam N, Subramanian S, Mitchell JB, Krishna MC. Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI. Proc. Natl. Acad. Sci. USA, 2009; 106(42): 17 898-17 903.
228. McPhail LD, Robinson SP. Intrinsic susceptibility MR imaging of chemically induced rat mammary tumors: relationship to histologic assessment of hypoxia and fibrosis. Radiology, 2010; 254(1): 110-118.
229. Seddon BM, Payne GS, Simmons L, Ruddle R, Grimshaw R, Tan S, Turner A, Raynaud F, Halbert G, Leach MO, Judson I, Workman P. A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin. Cancer Res. 2003; 9(14): 5101-5112.
230. 19F magnetic resonance spectroscopy. Br. J. Cancer, 2009; 101(11): 1860-1868.
231. Mees G, Dierckx R, Vangestel C, Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur. J. Nucl. Med. Mol. Imaging, 2009; 36: 1674-1686.
232. Laking G, Price P. Radionuclide imaging of perfusion and hypoxia. Eur. J. Nucl. Med. Mol. Imaging, 2010; 37(Suppl 1): S20-29.
233. Gillies RJ, Bhujwalla Evelhoch J, Garwood M, Neeman M, Robinson CH, Sotak CH, Van Der Sanden Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia, 2000; 2(1): 139-151.
234. Gillies RJ, Raghunand N, Garcia-Martin ML, Gatenby RA. pH imaging. A review of pH measurement methods and applications in cancers. IEEE Eng. Med. Biol. Mag. 2004; 2385: 57-64.
235. 13C-labelled bicarbonate. Nature, 2008; 453(7197): 940-943.
236. 11C]DMO and positron emission tomography. Ann. Neurol. 1985; 17: 70-79.
237. Thews O, Dillenburg W, Fellner M, Buchholz HG, Bausbacher N, Schreckenberger M, Rosch F. Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: in vivo imaging with (68)Ga-labelled PET tracer. Eur. J. Nucl. Med. Mol. Imaging, 2010; 37(10): 1935-1942.
238. 13C magnetic resonance imaging and spectroscopy. Nat. Med. 2007; 13(11): 1382-1387.
239. 13C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia, 2009; 11(6): 574-582.